Cipla Trims Staff At Indian Plant As It Eyes Costs
Executive Summary
The rumor mill has it that Cipla has effected significant staff cuts at its Pithampur facility in India, as it keeps a sharp eye on costs and drives efficiencies at its manufacturing operations. But the company isn’t saying much except that it routinely conducts "performance-based reviews."
You may also be interested in...
Cutbacks Rise As Indian Pharma Tightens Control On Costs
Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.
Sun To Trim US Manufacturing, Over 90 Jobs At Stake
Sun Pharma is consolidating its production activities in the US transferring operations out of its Cranbury site to the one in New Brunswick. Close to 100 jobs are expected to be affected.
Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key
Massive reorganization efforts are underway at Dr Reddy’s as it recalibrates costs; an antibiotics site is expected to be sold soon as part of these efforts and more may be in store. Management commentary was, however, upbeat around the growth outlook for the US business, with visibility of 15-20 launches in FY 2019.